Evidence map›Paper›PMID 39155562›Full record

ArticleCPT: pharmacometrics & systems pharmacology2024

Enhancing inclusivity in clinical trials: Model-informed drug development for pregnant individuals in the era of personalized medicine.

André Dallmann, Peter L Bonate, Janelle Burnham, Blessy George, Lynne Yao, Jane Knöchel

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

André DallmannBayer HealthCare SAS, Lille, France, on behalf of: Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.ORCID https://orcid.org/0000-0003-1108-5719
Peter L BonateEarly Development, New Technologies Group, Astellas, Northbrook, Illinois, USA.
Janelle BurnhamGlobal Product Development, Clinical Development and Operations, Pfizer Inc, New York, New York, USA.ORCID https://orcid.org/0000-0003-3896-2849
Blessy GeorgeDivision of Pharmacology-Toxicology for Immunology and Inflammation, Office of Immunology and Inflammation, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.ORCID https://orcid.org/0000-0002-8988-4601
Lynne YaoDivision of Pediatrics and Maternal Health, Office of Rare Diseases, Pediatrics, Urologic, and Reproductive Medicine, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Jane KnöchelClinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID https://orcid.org/0000-0001-9839-2433

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39155562
PMCPMC11578124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.